INDUSTRY INSIGHTS

• Unlocking ROI And Efficiency In Drug Development

  A Tufts University analysis modeled the eNPV gains, ROI, and timeline reductions possible when CDMO and CRO functions are consolidated, finding consistent benefits across mAbs, small molecules, and multiple development phases.

• Coordinated Drug Development As An Execution Framework

  When clinical research, CMC, manufacturing, and supply operate in silos, every phase transition resets alignment. Here, authors examine what changes when those functions operate within a shared execution framework.

• Quality As A Strategic Differentiator In Drug Development

  When quality functions as an operational discipline rather than a downstream control, it stabilizes complex drug development programs rather than slowing them down. This paper examines what that requires in practice.

• Guidelines For Structuring A First-In-Human Clinical Trial Application Dossier

  Preparing a first-in-human clinical trial application dossier involves navigating real uncertainty about how much CMC detail regulators expect at this early stage.

• A Practical Guide To Writing Robust CMC Dossier Modules For First-In-Human Trials

  A practical checklist covering the key CMC modules required for first-in-human CTD submissions, with guidance on characterization, manufacturing controls, stability, and patient safety documentation.

• Exploring 4 Patient-Centric Trends Shaping Today's Biopharma Landscape

  Patient centricity is reshaping pharma drug development through supply chain resiliency, decentralized trials, and patient-friendly formulations. Learn what these shifts mean for your pipeline strategy.

• An Insider's View On CDMO Services For Biologics

  Maider Parikh, VP of Commercial Operations, reveals how top biopharma teams are tackling timeline pressure, regulatory complexity, and supply chain risk. Access the full Q&A to benchmark your approach.

• What 'One Team' Really Means In Drug Development

  Replace silos with a unified drug development approach to align earlier, improve handoffs, and reduce surprises through shared visibility and proactive coordination.

• How To Maximize Pipeline Value And Enhance eNPV

  Find out how reducing vendor fragmentation can improve program continuity, minimize delays, and support more predictable development outcomes.

• Strategies For Robust Process Characterization And Validation To Accelerate Biologics Manufacturing

  Uncover how data-driven process design, effective technology transfer, and robust process characterization can accelerate validation readiness and help move biologics from development to commercial success faster.

• Early-Stage Biotech: The Wrong Outsourcing Strategy Costs More Than Time

  Turn scientific promise into sustained progress — choose a development model that minimizes risk, protects funding milestones, and helps your early-stage biotech move forward with speed, confidence, and strategic clarity.

• FIH: Reach Milestones Sooner With A Technology-Driven Approach

  Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

• The Science Of Cell Line Development For Biologics

  Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

• What's The Real Challenge In Biologic Manufacturing Scale-up? It's Not Capacity — It's Demand

  As you plan your next stage of scale-up, take a moment to evaluate whether your manufacturing strategy is built around capacity — or around evolving market demand.

• CDMO Checklist To Launch Your Molecule Globally

  Taking the time to evaluate your outsourcing needs and choose the right CDMO partner from the start can help you launch your new drug worldwide with confidence.

• Targeting Cancer With Therapeutic Antibodies

  Advancements in mAbs are paving the way for new antibody-based drugs for cancer treatment, making it essential for sponsors to accelerate early development and overcome production challenges.